Vamorolone

SKU: orb1307625

Description

Vamorolone (VBP15) is an orally bioavailable dissociative steroid that potently inhibits NF-κB, providing anti-inflammatory and membrane-stabilizing effects. It has demonstrated efficacy in improving outcomes in muscular dystrophy models while exhibiting a reduced side-effect profile compared to traditional corticosteroids in preclinical research.

Research Area

Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 13209-41-1
• MW: 356.46
• Purity: 99.57% (May vary between batches)
• Formula: C₂₂H₂₈O₄
• SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)CC=C1[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
• Target: NF-κB,Glucocorticoid Receptor
• Solubility: DMSO:62.5 mg/mL (175.34 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.61 mM)

Bioactivity

• In Vivo:
  Vamorolone (30 mg/kg; p.o.; daily for 20 days) decreases CNS Inflammation in murine experimental autoimmune encephalomyelitis. Vamorolone (5-30 mg/kg; cherry syrup) displays a superior side effect profile compared to pharmacological glucocorticoids in mdx mice .
  Read more...
• In Vitro:
  Vamorolone is a first-in-class mineralocorticoid receptor antagonist/dissociative glucocorticoid receptor ligand. Vamorolone inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor and mineralocorticoid receptor. Vamorolone (0.1, 1μM; 30 minutes) decreases the production of IL1βand CCL5 inflammatory mediators in primary human macrophages .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

dystrophy, Duchenne, muscular, inhibit, inflammation, Mineralocorticoid Receptor, NF-κB, NFκB, NF-kB, NFkB, Nuclear factor-κB, Nuclear factor-kappaB, membrane, Inhibitor, glucocorticoid, GlucocorticoidReceptor, Glucocorticoid Receptor, repair, Vamorolone, VBP 15, VBP15, VBP-15

Compound Identifiers

PubChem CID

3035000